Cargando…

Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach

SIMPLE SUMMARY: Stereotactic body radiation therapy (SBRT) allows for the high-precision delivery of a large dose of radiation to a small area. SBRT has shown overall survival benefits in a variety of oligometastatic cancers in recent trials. However, prospective data in recurrent or oligometastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Sherwani, Zohaib, Parikh, Shreel, Yegya-Raman, Nikhil, McKenna, Kelly, Deek, Matthew, Jabbour, Salma, Hathout, Lara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340138/
https://www.ncbi.nlm.nih.gov/pubmed/37444636
http://dx.doi.org/10.3390/cancers15133526
_version_ 1785072006887112704
author Sherwani, Zohaib
Parikh, Shreel
Yegya-Raman, Nikhil
McKenna, Kelly
Deek, Matthew
Jabbour, Salma
Hathout, Lara
author_facet Sherwani, Zohaib
Parikh, Shreel
Yegya-Raman, Nikhil
McKenna, Kelly
Deek, Matthew
Jabbour, Salma
Hathout, Lara
author_sort Sherwani, Zohaib
collection PubMed
description SIMPLE SUMMARY: Stereotactic body radiation therapy (SBRT) allows for the high-precision delivery of a large dose of radiation to a small area. SBRT has shown overall survival benefits in a variety of oligometastatic cancers in recent trials. However, prospective data in recurrent or oligometastatic gynecologic cancer are limited. The current literature shows that SBRT in gynecologic oligometastases is safe and effective, resulting in 2-year local control rates exceeding 80%. However, progression outside of the radiated field remains a significant issue despite local control. This review discusses the advantages, limitations, and future directions of SBRT in gynecologic oligometastases including a discussion on the synergistic effects of combination with immunotherapy. ABSTRACT: Historically, the role of radiation in gynecological metastatic disease involved palliation for pain or bleeding. Stereotactic Body Radiation Therapy (SBRT) has shown survival benefits in oligometastatic disease from varying primary histologies in recent randomized trials. However, gynecologic primary oligometastases have been underrepresented in these trials. Recent studies across gynecological malignancy types have similarly shown favorable outcomes and acceptable toxicities from treating recurrent or oligometastatic gynecologic cancer (ROMGC) patients with definitive radiation therapy. The largest body of literature reported on the use of SBRT in ovarian cancer, which was found to be an effective option, especially in the setting of chemo-resistant disease. Despite the encouraging outcomes using SBRT in oligometastatic gynecologic malignancies, SBRT remains underutilized given the lack of randomized studies studying ROMGC with long term follow-up. While waiting for future prospective trials to establish the role of SBRT as the standard of care in ROMGC patients, this review focuses on reporting the advantages and drawbacks of this technique and examines the current literature to help guide patient centered treatment decisions.
format Online
Article
Text
id pubmed-10340138
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103401382023-07-14 Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach Sherwani, Zohaib Parikh, Shreel Yegya-Raman, Nikhil McKenna, Kelly Deek, Matthew Jabbour, Salma Hathout, Lara Cancers (Basel) Review SIMPLE SUMMARY: Stereotactic body radiation therapy (SBRT) allows for the high-precision delivery of a large dose of radiation to a small area. SBRT has shown overall survival benefits in a variety of oligometastatic cancers in recent trials. However, prospective data in recurrent or oligometastatic gynecologic cancer are limited. The current literature shows that SBRT in gynecologic oligometastases is safe and effective, resulting in 2-year local control rates exceeding 80%. However, progression outside of the radiated field remains a significant issue despite local control. This review discusses the advantages, limitations, and future directions of SBRT in gynecologic oligometastases including a discussion on the synergistic effects of combination with immunotherapy. ABSTRACT: Historically, the role of radiation in gynecological metastatic disease involved palliation for pain or bleeding. Stereotactic Body Radiation Therapy (SBRT) has shown survival benefits in oligometastatic disease from varying primary histologies in recent randomized trials. However, gynecologic primary oligometastases have been underrepresented in these trials. Recent studies across gynecological malignancy types have similarly shown favorable outcomes and acceptable toxicities from treating recurrent or oligometastatic gynecologic cancer (ROMGC) patients with definitive radiation therapy. The largest body of literature reported on the use of SBRT in ovarian cancer, which was found to be an effective option, especially in the setting of chemo-resistant disease. Despite the encouraging outcomes using SBRT in oligometastatic gynecologic malignancies, SBRT remains underutilized given the lack of randomized studies studying ROMGC with long term follow-up. While waiting for future prospective trials to establish the role of SBRT as the standard of care in ROMGC patients, this review focuses on reporting the advantages and drawbacks of this technique and examines the current literature to help guide patient centered treatment decisions. MDPI 2023-07-07 /pmc/articles/PMC10340138/ /pubmed/37444636 http://dx.doi.org/10.3390/cancers15133526 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sherwani, Zohaib
Parikh, Shreel
Yegya-Raman, Nikhil
McKenna, Kelly
Deek, Matthew
Jabbour, Salma
Hathout, Lara
Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach
title Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach
title_full Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach
title_fullStr Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach
title_full_unstemmed Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach
title_short Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach
title_sort stereotactic body radiation therapy in gynecologic oligometastases: an effective but underutilized approach
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340138/
https://www.ncbi.nlm.nih.gov/pubmed/37444636
http://dx.doi.org/10.3390/cancers15133526
work_keys_str_mv AT sherwanizohaib stereotacticbodyradiationtherapyingynecologicoligometastasesaneffectivebutunderutilizedapproach
AT parikhshreel stereotacticbodyradiationtherapyingynecologicoligometastasesaneffectivebutunderutilizedapproach
AT yegyaramannikhil stereotacticbodyradiationtherapyingynecologicoligometastasesaneffectivebutunderutilizedapproach
AT mckennakelly stereotacticbodyradiationtherapyingynecologicoligometastasesaneffectivebutunderutilizedapproach
AT deekmatthew stereotacticbodyradiationtherapyingynecologicoligometastasesaneffectivebutunderutilizedapproach
AT jabboursalma stereotacticbodyradiationtherapyingynecologicoligometastasesaneffectivebutunderutilizedapproach
AT hathoutlara stereotacticbodyradiationtherapyingynecologicoligometastasesaneffectivebutunderutilizedapproach